Oregon

Oregon’s framework keeps evolving. Local governments may refer ordinances to voters to prohibit psilocybin manufacturers and service centres in their jurisdictions, and OHA must stop licensing affected premises until the next statewide general election process resolves the measure. That local opt-out structure materially shapes access geography.###

OPS also now runs a more formalised data and oversight system. OHA states that, beginning 1 Jan 2025, service centres must collect and submit specified client-level and service-centre-level data under SB 303, with quarterly aggregated reporting through the TLC system. In parallel, HB 2387 was signed in 2025 and, from 1 Jan 2026, allows facilitators who also hold certain Oregon professional licences to provide healthcare or behavioural-health services during preparation and integration sessions; related 2025 rulemaking also added veteran-status data collection and psilocin labelling requirements.###

Oregon’s broader drug-possession environment is no longer the Measure 110 model of early 2021–2024. HB 4002 increased penalties for unlawful possession of controlled substances from 1 Sep 2024, even while separate licensed psilocybin conduct remains authorised under ORS 475A. That distinction is essential for access and enforcement reporting.###

Oregon is now also a policy-research jurisdiction. In Feb 2026, OHSU announced a five-year, $3.3 million National Institute on Drug Abuse award to study the safety and effectiveness of state-regulated psilocybin services in community settings, led through the Oregon Psychedelic Evaluation Nexus. OHSU said the initiative is the first federally funded work to study legal psychedelic services delivered in community settings.###

The OHSU story also provides unusually concrete scale indicators: researchers had already gathered preliminary data from more than 300 Oregon psilocybin-service clients willing to participate and aimed to enrol at least 1,600 participants over five years. ClinicalTrials.gov search results also point to Oregon-based studies including a Portland low-income group psilocybin-assisted therapy feasibility study and a study on psilocybin microdosing plus meditation.###

Oregon has the most developed implementation machinery in this set. OPS sits inside OHA’s Public Health Division; it licenses and regulates manufacturers, service centres, facilitators and laboratories, maintains licensing and compliance data, and now receives quarterly service-centre reporting. OHA’s 2024 year-in-review recorded 55 complaints, two licence application denials, five final orders for administrative violations, 18,424 psilocybin products sold to clients for administration sessions, and 103 reported emergency-service contacts by 31 Dec 2024.###

Rulemaking remains active. OHA’s administrative-rules page states that a temporary rule related to service-centre location requirements became permanent on 22 Jan 2026. OPS also convened a 2026 potency workgroup after licensee concerns about products with high psilocin content being used in lower-dose sessions. Facilitator scope remains formally non-directive, with only limited dual-licence health-service activity permitted in preparation and integration settings.###

Oregon’s ecosystem is now layered: regulator, academic evaluators, service businesses, training programmes, and advisory structures all exist in public view. OHA’s 2024 year-in-review highlights continuing activity by the Oregon Psilocybin Advisory Board and subcommittees, licensee lunch forums, new operational resources, and public listening sessions.###

On the research side, OHSU and OPEN are the clearest institutional anchors. OHSU’s integrative-health research pages also identify its SNAP lab as working on MDMA- and psilocybin-related research themes, and the 2026 NIDA award positions Oregon as a nationally important natural experiment in community-setting supervised psilocybin services.###

Over the next 12 to 24 months, Oregon will probably generate more implementation evidence than any other state. The highest-value signals will be quarterly data releases, safety and utilisation patterns, dual-licensure uptake after HB 2387, and whether local opt-out geography continues to constrain supply.###

On the access side, the main open question is not legality but affordability and service distribution. Oregon has proved that legal supervised psilocybin services can operate; the next phase is whether the system becomes more geographically available, more professionally integrated, and more empirically legible to payers, policymakers and researchers. Public reimbursement for state-regulated psilocybin services remains unverified and should be treated cautiously.###